MindWalk Holdings Corp. Common Stock (HYFT) Stock Price

HYFTStock

$1.31−20.12%52W

Market Cap$61.72M

P/E—

PEG Ratio—

Div yield—

Beta0.78

HYFT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)1.11%

Price vs S&P 500 (4W)-9.56%

VGM Score42.84

Book Value / Share (Quarterly)$0.10

P/TBV (Annual)6.69x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-9.03%

Cash Flow / Share (Quarterly)$-0.20

Price vs S&P 500 (YTD)-39.95%

Gross Margin (TTM)60.79%

Net Profit Margin (TTM)-105.20%

EPS (TTM)$-0.26

10-Day Avg Trading Volume0.49M

EPS Excl Extra (TTM)$-0.26

Revenue Growth (5Y)-2.78%

EPS (Annual)$-0.21

ROI (Annual)-91.32%

Gross Margin (Annual)58.80%

Net Profit Margin (5Y Avg)-107.73%

Cash / Share (Quarterly)$0.11

Revenue Growth QoQ (YoY)21.29%

ROA (Last FY)-65.26%

Revenue Growth TTM (YoY)-27.60%

EBITD / Share (TTM)$-0.25

ROE (5Y Avg)-78.99%

Operating Margin (TTM)-104.16%

Cash Flow / Share (Annual)$-0.19

P/B Ratio12.63x

P/B Ratio (Quarterly)12.40x

Net Income / Employee (Annual)$-96,804

EV / Revenue (TTM)5.12x

Net Interest Coverage (TTM)-112.52x

ROA (TTM)-77.80%

EPS Incl Extra (Annual)$-0.21

Current Ratio (Annual)2.80x

Quick Ratio (Quarterly)1.63x

3-Month Avg Trading Volume0.25M

52-Week Price Return-20.12%

Revenue / Employee (TTM)$112,584

Tangible BV / Share (Quarterly)$0.10

P/S Ratio (Annual)5.61x

Asset Turnover (Annual)0.73x

52-Week High$2.12

Operating Margin (5Y Avg)-118.61%

EPS Excl Extra (Annual)$-0.21

CapEx CAGR (5Y)-21.96%

26-Week Price Return11.02%

Quick Ratio (Annual)2.58x

13-Week Price Return-10.27%

Total Debt / Equity (Annual)0.30x

Current Ratio (Quarterly)1.84x

Enterprise Value$58.82M

Revenue / Share Growth (5Y)-20.96%

Asset Turnover (TTM)0.74x

Revenue / Employee (Annual)$107,913

Inventory Turnover (Annual)4.96x

Pretax Margin (Annual)-99.96%

Cash / Share (Annual)$0.17

3-Month Return Std Dev89.25%

Gross Margin (5Y Avg)48.80%

Net Income / Employee (TTM)$-118,457

ROE (Last FY)-118.72%

Net Interest Coverage (Annual)-35.10x

EPS Basic Excl Extra (Annual)$-0.21

P/FCF (TTM)97.99x

Receivables Turnover (TTM)6.22x

Total Debt / Equity (Quarterly)0.50x

EPS Incl Extra (TTM)$-0.26

Receivables Turnover (Annual)4.00x

ROI (TTM)-104.46%

P/S Ratio (TTM)5.38x

Pretax Margin (5Y Avg)-117.33%

Revenue / Share (Annual)$0.24

Tangible BV / Share (Annual)$0.18

Price vs S&P 500 (52W)-35.65%

Year-to-Date Return-28.02%

5-Day Price Return-6.43%

EPS Normalized (Annual)$-0.21

ROA (5Y Avg)-46.11%

Net Profit Margin (Annual)-89.66%

Month-to-Date Return-1.13%

EBITD / Share (Annual)$-0.24

Operating Margin (Annual)-99.29%

LT Debt / Equity (Annual)0.03x

ROI (5Y Avg)-58.46%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.26

P/TBV (Quarterly)12.40x

P/B Ratio (Annual)6.69x

Inventory Turnover (TTM)11.21x

Pretax Margin (TTM)-106.59%

Book Value / Share (Annual)$0.18

Price vs S&P 500 (13W)-12.96%

Beta0.78x

Revenue / Share (TTM)$0.25

ROE (TTM)-133.33%

52-Week Low$0.70

vGradeD

gGradeD

mGradeC

vgmGradeC

HYFT Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Sep 14, 2026	-$0.04	-$0.07	-70.88%(-$0.03)
Q1 2026	Jul 22, 2026	-$0.04	-$0.04	-6.51%(-$0.00)
Q4 2025	Mar 12, 2026	-$0.03	-$0.04	-63.42%(-$0.01)
Q3 2025	Dec 15, 2025	-$0.01	-$0.04	-238.53%(-$0.03)
Q2 2025	Sep 15, 2025	-$0.03	-$0.04	-17.93%(-$0.01)
Q1 2025	Jul 29, 2025	-$0.02	-$0.03	-4.14%(-$0.00)

HYFT Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.11

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
HYFTMindWalk Holdings Corp. Common Stock	D	D	C	5.4x	-27.6%	60.8%	—	$1.31
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About MindWalk Holdings Corp. Common Stock

MindWalk Holdings Corp is a bio-native AI company that accelerates drug discovery and development using proprietary HYFT technology and its LensAI platform. The company integrates molecular sequence, structure, function, and literature data into a unified computational framework, paired with an internal wet lab for validation. This integrated approach enables rapid applications in epitope mapping, protein design, vaccine exploration, and large-scale biologics analysis, helping to advance drug candidates faster from discovery to validation.